Initiation of biological agents in patients with ankylosing spondylitis: Results of a Delphi study by the ASAS Group

Annals of the Rheumatic Diseases

Volumn 62, Issue 9, 2003, Pages 812-816

  Pham, T ^b,c   Van Der Heijde, D ^d   Calin, A ^e   Khan, M A ^f   Van Der Linden, Sj ^d   Bellamy, N ^g   Dougados, M ^a  

^a René Descartes University ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^f METROHEALTH MEDICAL CENTER   (United States)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENTHESITIS; HUMAN; MAJOR CLINICAL STUDY; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DELPHI TECHNIQUE; HEALTH STATUS INDICATORS; HUMANS; PATIENT SELECTION; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042508748     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.9.812     Document Type: Article

References (20)

1. Edmonds JP, Scott DL, Furst DE, Paulus HE. New classification of antirheumatic drugs. The evolution of a concept. J Rheumatol 1993;20:585-7.
2. van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 1999;26:945-7.
3. Bathon JM, Martin RW, Freischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
4. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
5. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:495-505.
6. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
7. Braun J, Brandt J, Listing J, Zink A, Alten R, Galder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
8. van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
9. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment af active ankylosing spondylitis with the anti-tumor necrosis factor alpha monaclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
10. Kruithof E, van den Bosch F, Baeten D, De Keyser F, Mielants H, Veys EM. TNF-alpha blockade with infliximab in patients with active spondyloarthropathy: follow-up of one year maintenance regimen [abstract]. Ann Rheum Dis 2001;60 (suppl I):59.
11. Stone MA, Salonen DC, Lax MJ, Payne U, Lapp V, Inman RD. Clinical and imaging correlates of response to treatment with Infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
12. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8
13. Zink A, Listing J, Klindworth C, Zeidler H; German Collaboratrive Arthritis Centres. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis 2001;60:199-206.
14. Braun J, Sieper J. [Reply to letter by D'Agostino et al.] Arthritis Rheum 2002;46:841-2.
15. Dayer JM, Krane SM. Anti-TNF-alpha therapy for ankylosing spondylitis - a specific or nonspecific treatment? N Engl J Med 2002;346:1399-400.
16. van der Heijde D, van der Linden S, Dougados M, Bellamy N, Russell AS, Edmonds J. Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 1999;26:1003-5.
17. van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 1999;26:945-7.
18. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
19. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
20. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995;21:117-28.